<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192812</url>
  </required_header>
  <id_info>
    <org_study_id>ALKU RESEARCH HOSPİTAL</org_study_id>
    <nct_id>NCT04192812</nct_id>
  </id_info>
  <brief_title>PREOPERATIVE GONADOTROPINE-RELEASING HORMONE AGONIST THERAPY BEFORE SURGERY FOR UTERİN FIBROIDS</brief_title>
  <official_title>THE EFFICACY OF PREOPERATIVE USAGE OF GONADOTROPINE-RELEASING HORMONE AGONIST IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkü Alanya Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkü Alanya Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterin fibroids are the most common operation indication for hysterectomy. Dyring
      laparoscopic hysterectomy the amount of bleeding is a great difficulty.There are a lot of
      clinical researchs to reduce the haemorrhage during open hysterectomy but not laparoscopic
      procedure. In ALKU ERH clinic, researchers decided to smaller the size of fibroid by using
      GnRH analogues before total laparoscopic hysterectomy to reduce the haemorrhage amount.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After randomising patients to two groups, one of the group will be controle group and the
      other group will be working group and researchers decided to use 3,75 mg leuprolide acetate
      as GnRHa subcutanously in every four week, throughout 3 months before surgery to the working
      group, researchers will record intraoperative amount of bleeding by measuring the blood in
      suction scale, the duration of surgery, difference between preoperative haemoglobin levels
      and uterin weight. researchers will comparise all theese parameters ibn to two groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>PROSPECTİVE RANDOMİSED CONTROLLED TRİAL</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AMOUNT OF BLEEDİNG</measure>
    <time_frame>0 minute - 180 minute</time_frame>
    <description>WHOLE AMOUNT OF BLEEDING DURING SURGERY</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DURATION AF SURGERY</measure>
    <time_frame>0 MINUTE- 180 MINUTE</time_frame>
    <description>TIME BETWEEN INITIAL AND END OF SURGERY</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Uterine Fibroid</condition>
  <condition>Gonadotropin-Releasing Hormone-Dependent Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>GnRHa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,75 MG LEUPROLIDE ACETATE FOR EVERY 4 WEEKS THROUGHOUT 3 MONTHS BEFORE SURGERY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no GnRHa</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NO TREATMENT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS</intervention_name>
    <description>THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS</description>
    <arm_group_label>GnRHa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NO GnRHa</intervention_name>
    <description>THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS</description>
    <arm_group_label>no GnRHa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MYOMA UTERI

          -  APPROPİATE FOR LAPAROSCOPY

        Exclusion Criteria:

          -  MALİGNANCY
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MERAL TUĞBA ÇİMŞİR</last_name>
    <role>Principal Investigator</role>
    <affiliation>ALKU EDUCATİON AND RESEARCH HOSPITAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERAL TUĞBA ÇİMŞİR</last_name>
    <phone>05064742272</phone>
    <email>dr.tugbaacar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alku Alanya Education and Research Hospital</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>MERAL TUĞBA ÇİMŞİR</last_name>
      <phone>05064742272</phone>
      <email>DR.TUGBAACAR@GMAİL.COM</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alkü Alanya Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>MERAL TUĞBA ÇİMŞİR</investigator_full_name>
    <investigator_title>ASSOCIATE PROFESSOR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>5 YEARS</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

